BIOGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 221.5 USD | -0.56% |
|
+1.83% | -14.40% |
| 05-09 | MOVES -Lazard hires veteran healthcare dealmaker Colocci as vice chairman | RE |
| 05-08 | Redburn Atlantic Adjusts Price Target on Biogen to $235 From $275, Keeps Neutral Rating | MT |
| Sales 2024 * | 9.52B 760B | Sales 2025 * | 9.55B 762B | Capitalization | 32.25B 2,575B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.9B 151B | Net income 2025 * | 2.21B 177B | EV / Sales 2024 * | 3.7 x |
| Net Debt 2024 * | 3.01B 241B | Net Debt 2025 * | 536M 42.78B | EV / Sales 2025 * | 3.43 x |
| P/E ratio 2024 * |
17.1
x | P/E ratio 2025 * |
14.8
x | Employees | 7,570 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.81% |
More Fundamentals
* Assessed data
More news
Latest transcript on Biogen Inc.
More recommendations
More press releases
More news
| 1 day | -0.56% | ||
| 1 week | +1.83% | ||
| Current month | +3.11% | ||
| 1 month | +11.77% | ||
| 3 months | -9.50% | ||
| 6 months | -1.46% | ||
| Current year | -14.40% |
1 week
216.08
223.95
1 month
189.44223.95
Current year
189.44268.30
1 year
189.44319.76
3 years
187.16468.55
5 years
187.16468.55
10 years
187.16480.18
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 13/11/22 | |
| Director of Finance/CFO | 60 | 14/08/20 | |
Nicole Murphy
COO | Chief Operating Officer | - | 31/12/14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 31/12/09 |
William Hawkins
BRD | Director/Board Member | 70 | 18/06/19 |
Caroline Dorsa
CHM | Chairman | 64 | 02/01/10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.30% | 0 M€ | -2.17% | - | |
| 3.92% | 0 M€ | 0.00% | - | |
| 3.75% | 0 M€ | 0.00% | - | |
| 2.39% | 0 M€ | +6.29% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/05/24 | 221.5 | -0.56% | 655,151 |
| 09/05/24 | 222.8 | +1.38% | 754,595 |
| 08/05/24 | 219.7 | +0.37% | 758,528 |
| 07/05/24 | 218.9 | -1.13% | 1,156,500 |
| 06/05/24 | 221.4 | +1.80% | 1,199,848 |
Delayed Quote Nasdaq, May 10, 2024 at 09:00 pm
More quotes
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
221.5
USD
Average target price
285.9
USD
Spread / Average Target
+29.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.40% | 32.25B | |
| -2.61% | 89.08B | |
| +3.55% | 40.9B | |
| +55.89% | 25.14B | |
| -15.96% | 15.39B | |
| -15.50% | 11.91B | |
| -41.29% | 11.89B | |
| -11.75% | 11.64B | |
| +7.87% | 9.03B | |
| -3.16% | 8.62B |
- Stock Market
- Equities
- BIIB Stock
